Some embodiments of the invention relate to methods of administering orally a therapeutically effective pharmaceutical formulation of between about 3,000 micrograms to about 12,000 micrograms of allicin in a pharmaceutical dosage form to a patient with a herpes simplex viral infection, the therapeutically effective pharmaceutical formulation of allicin for increasing a human immune system activity in the patient during a reactivation of a herpes simplex virus causing a prodromal phase of the herpes simplex virus outbreak in the patient, the increasing of the human immune system activity in the patient for suppressing a herpes simplex viral symptom in the patient. In a preferred embodiment of the invention, an initial allicin dose of between about 7,200 micrograms to about 12,000 micrograms is administered once to an HSV patient and then at hourly or daily intervals, nine allicin doses additional of between about 3,000 micrograms to about 4800 micrograms are administered to the HSV patient.
